当前位置: 首页 >> 检索结果
261. Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes.
作者: Rosalie A Scholtes.;Anne C Hesp.;Charlotte M Mosterd.;Frank Geurts.;Ewout J Hoorn.;Daan J Touw.;Merle M Krebber.;Jaap A Joles.;Hiddo J L Heerspink.;Daniël H van Raalte.
来源: Circulation. 2022年146卷24期1895-1897页 262. BioMatrix Versus Orsiro Stents for Coronary Artery Disease: A Multicenter, Randomized, Open-Label Study.
作者: Chang-Hwan Yoon.;Ju-Seung Kwun.;Young Jin Choi.;Jin Joo Park.;Si-Hyuck Kang.;Sun-Hwa Kim.;Jung-Won Suh.;Tae-Jin Youn.;Myeong-Kon Kim.;Kwang Soo Cha.;Seung-Hwan Lee.;Bum-Kee Hong.;Seung-Woon Rha.;Woong Chol Kang.;Jae-Hwan Lee.;Sang-Hyun Kim.;In-Ho Chae.
来源: Circ Cardiovasc Interv. 2023年16卷1期e012307页
Comparative studies of ultrathin-strut biodegradable polymer sirolimus-eluting stent (BP-SES) have reported promising results and validated its excellent outcomes in terms of safety and efficacy. However, there are limited studies comparing BP drug-eluting stents with struts of different thicknesses. We compared the long-term clinical outcomes of patients treated with an ultrathin-strut BP-SES or a thick-strut biodegradable polymer biolimus-eluting stent (BP-BES).
263. First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).
作者: Bruce S Stambler.;Francis Plat.;Philip T Sager.;Silvia Shardonofsky.;Douglas Wight.;Diane Potvin.;A Shekhar Pandey.;James E Ip.;Benoit Coutu.;Blandine Mondésert.;Laurence D Sterns.;Matthew Bennett.;Jeffrey L Anderson.;Roger Damle.;Ronald Haberman.;A John Camm.
来源: Circ Arrhythm Electrophysiol. 2022年15卷12期e010915页
Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medically supervised intervention. Intranasal etripamil, is an investigational fast-acting, nondihydropyridine, L-type calcium channel blocker, designed for unsupervised self-administration to terminate atrioventricular nodal-dependent PSVT. Phase 2 results showed potential safety and efficacy of etripamil in 104 patients with PSVT.
264. Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
作者: Eun Ho Choo.;Ik Jun Choi.;Sungmin Lim.;Donggyu Moon.;Chan Joon Kim.;Mahn-Won Park.;Min Chul Kim.;Byung-Hee Hwang.;Kwan Yong Lee.;Yun Seok Choi.;Hee-Yeol Kim.;Ki-Dong Yoo.;Doo Soo Jeon.;Youngkeun Ahn.;Kiyuk Chang.; .
来源: Circ Cardiovasc Interv. 2022年15卷12期e012157页
Data regarding prognosis and management after nuisance bleeding (NB) is limited. The purpose was to examine the prognostic significance of NB in patients receiving potent dual antiplatelet treatment (DAPT) after acute myocardial infarction and the impact of de-escalation of DAPT on clinical outcomes thereafter.
265. Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants.
作者: Michael V Di Maria.;David J Goldberg.;Victor Zak.;Chenwei Hu.;Adam M Lubert.;Andreea Dragulescu.;Andrew S Mackie.;Andrew McCrary.;Angela Weingarten.;Anitha Parthiban.;Benjamin Goot.;Bryan H Goldstein.;Carolyn Taylor.;Christopher Lindblade.;Christopher J Petit.;Christopher Spurney.;David M Harrild.;Elaine M Urbina.;Eleanor Schuchardt.;Gi Beom Kim.;Ja Kyoung Yoon.;Jamie N Colombo.;Matthew D Files.;Megan Schoessling.;Peter Ermis.;Pierre C Wong.;Ruchira Garg.;Sara K Swanson.;Shaji C Menon.;Shubhika Srivastava.;Thor Thorsson.;Tiffanie R Johnson.;Usha S Krishnan.;Stephen M Paridon.;Peter C Frommelt.; .
来源: Circ Cardiovasc Imaging. 2022年15卷11期e013676页
The FUEL trial (Fontan Udenafil Exercise Longitudinal) demonstrated statistical improvements in exercise capacity following 6 months of treatment with udenafil (87.5 mg po BID). The effect of udenafil on echocardiographic measures of single ventricle function in this cohort has not been studied.
266. Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH.
作者: Xue-Qiao Zhao.;Jie Sun.;Daniel S Hippe.;Daniel A Isquith.;Gador Canton.;Kiyofumi Yamada.;Niranjan Balu.;John R Crouse.;Todd J Anderson.;John Huston.;Kevin D O'Brien.;Thomas S Hatsukami.;Chun Yuan.; .
来源: Circ Cardiovasc Imaging. 2022年15卷11期e014229页
Intraplaque hemorrhage (IPH) is associated with plaque progression and ischemic events, and plaque lipid content (% lipid core) predicts the residual atherosclerotic cardiovascular disease risk. This study examined the impact of IPH on lipid content change in the setting of intensive lipid-lowering therapy.
267. Experiences Implementing a Suite of Decision Aids for Implantable Cardioverter Defibrillators: Qualitative Insights From the DECIDE-ICD Trial.
作者: Christopher E Knoepke.;Bryan C Wallace.;Larry A Allen.;Carmen L Lewis.;Sanjaya K Gupta.;Pamela N Peterson.;Daniel B Kramer.;Scott C Brancato.;Paul D Varosy.;John M Mandrola.;Wendy S Tzou.;Daniel D Matlock.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷11期e009352页
Shared decision making (SDM) is gaining importance in cardiology, including Centers for Medicare & Medicaid Services (CMS) reimbursement policies requiring documented SDM for patients considering primary prevention implantable cardioverter defibrillators. The DECIDE-ICD Trial (Decision Support Intervention for Patients offered implantable Cardioverter-Defibrillators) assessed the implementation and effectiveness of patient decision aids (DAs) using a stepped-wedge design at 7 sites. The purpose of this subanalysis was to qualitatively describe electrophysiology clinicians' experience implementing and using the DAs.
268. Improvements and Maintenance of Clinical and Functional Measures Among Rural Women: Strong Hearts, Healthy Communities-2. 0 Cluster Randomized Trial.
作者: Rebecca A Seguin-Fowler.;Galen D Eldridge.;Chad D Rethorst.;Meredith L Graham.;Margaret Demment.;David Strogatz.;Sara C Folta.;Jay E Maddock.;Miriam E Nelson.;Seungyeon Ha.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷11期e009333页
Cardiovascular disease is the leading cause of death in the United States; however, women and rural residents face notable health disparities compared with male and urban counterparts. Community-engaged programs hold promise to help address disparities through health behavior change and maintenance, the latter of which is critical to achieving clinical improvements and public health impact.
269. Quality of Life Trajectory and Its Mediators in Older Patients With Acute Decompensated Heart Failure Receiving a Multi-Domain Rehabilitation Intervention: Results From the Rehabilitation Therapy in Older Acute Heart Failure Patients Trial.
作者: David Whellan.;Melissa M McCarey.;Haiying Chen.;M Benjamin Nelson.;Amy M Pastva.;Pamela Duncan.;Robert J Mentz.;Dalane W Kitzman.;Gordon Reeves.;Shelby D Reed.
来源: Circ Heart Fail. 2022年15卷12期e009695页
As patients with heart failure experience worsening of their condition, including acute decompensated heart failure, quality of life deteriorates. However, the trajectory of quality of life changes and their determinants in the context of the Rehabilitation Therapy in Older Acute Heart Failure Patients trial physical rehabilitation intervention are unknown.
270. Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project).
作者: Alexander T Sandhu.;Fatima Rodriguez.;Summer Ngo.;Bhavik N Patel.;Domenico Mastrodicasa.;David Eng.;Nishith Khandwala.;Sujana Balla.;Doug Sousa.;David J Maron.
来源: Circulation. 2023年147卷9期703-714页
Coronary artery calcium (CAC) can be identified on nongated chest computed tomography (CT) scans, but this finding is not consistently incorporated into care. A deep learning algorithm enables opportunistic CAC screening of nongated chest CT scans. Our objective was to evaluate the effect of notifying clinicians and patients of incidental CAC on statin initiation.
271. Randomized Controlled Trial of a Smartphone-Based Intervention to Enhance 6-Minute Walk Distance During Breast Cancer Treatment: The SMART-BREAST Trial.
作者: Alexandra C Murphy.;Omar Farouque.;Anoop N Koshy.;Belinda Yeo.;Ron Dick.;Voltaire Nadurata.;Laura Roccisano.;Christopher Reid.;Matias B Yudi.
来源: Circulation. 2023年147卷7期614-616页 272. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
作者: Jeehoon Kang.;Kyung Woo Park.;Huijin Lee.;Doyeon Hwang.;Han-Mo Yang.;Seung-Woon Rha.;Jang-Whan Bae.;Nam Ho Lee.;Seung-Ho Hur.;Jung-Kyu Han.;Eun-Seok Shin.;Bon-Kwon Koo.;Hyo-Soo Kim.
来源: Circulation. 2023年147卷2期108-117页
Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Extended Antiplatelet Monotherapy) Extended study reports the posttrial follow-up results of the original HOST-EXAM trial.
273. Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study.
作者: Stephen J Foulkes.;Erin J Howden.;Mark J Haykowsky.;Yoland Antill.;Agus Salim.;Sophie S Nightingale.;Sherene Loi.;Piet Claus.;Kristel Janssens.;Amy M Mitchell.;Leah Wright.;Ben T Costello.;Anniina Lindqvist.;Lauren Burnham.;Imogen Wallace.;Robin M Daly.;Steve F Fraser.;André La Gerche.
来源: Circulation. 2023年147卷7期532-545页
Breast cancer survivors treated with anthracycline-based chemotherapy (AC) have increased risk of functional limitation and cardiac dysfunction. We conducted a 12-month randomized controlled trial in 104 patients with early-stage breast cancer scheduled for AC to determine whether 12 months of exercise training (ExT) could attenuate functional disability (primary end point), improve cardiorespiratory fitness (VO2peak), and prevent cardiac dysfunction.
274. Survival After Invasive or Conservative Management of Stable Coronary Disease.
作者: Judith S Hochman.;Rebecca Anthopolos.;Harmony R Reynolds.;Sripal Bangalore.;Yifan Xu.;Sean M O'Brien.;Stavroula Mavromichalis.;Michelle Chang.;Aira Contreras.;Yves Rosenberg.;Ruth Kirby.;Balram Bhargava.;Roxy Senior.;Ann Banfield.;Shaun G Goodman.;Renato D Lopes.;Radosław Pracoń.;José López-Sendón.;Aldo Pietro Maggioni.;Jonathan D Newman.;Jeffrey S Berger.;Mandeep S Sidhu.;Harvey D White.;Andrea B Troxel.;Robert A Harrington.;William E Boden.;Gregg W Stone.;Daniel B Mark.;John A Spertus.;David J Maron.; .
来源: Circulation. 2023年147卷1期8-19页
The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) compared an initial invasive versus an initial conservative management strategy for patients with chronic coronary disease and moderate or severe ischemia, with no major difference in most outcomes during a median of 3.2 years. Extended follow-up for mortality is ongoing.
275. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
作者: Holger Reinecke.;Christiane Engelbertz.;Rupert Bauersachs.;Günter Breithardt.;Hans-Herbert Echterhoff.;Joachim Gerß.;Karl Georg Haeusler.;Bernd Hewing.;Joachim Hoyer.;Sabine Juergensmeyer.;Thomas Klingenheben.;Guido Knapp.;Lars Christian Rump.;Hans Schmidt-Guertler.;Christoph Wanner.;Paulus Kirchhof.;Dennis Goerlich.
来源: Circulation. 2023年147卷4期296-309页
Non-vitamin K oral anticoagulants have become the standard therapy for preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF). The effectiveness and safety of non-vitamin K oral anticoagulants in patients on hemodialysis is not well known.
276. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.
作者: Sean D Pokorney.;Glenn M Chertow.;Hussein R Al-Khalidi.;Dianne Gallup.;Pat Dignacco.;Kurt Mussina.;Nisha Bansal.;Crystal A Gadegbeku.;David A Garcia.;Samira Garonzik.;Renato D Lopes.;Kenneth W Mahaffey.;Kelly Matsuda.;John P Middleton.;Jennifer A Rymer.;George H Sands.;Ravi Thadhani.;Kevin L Thomas.;Jeffrey B Washam.;Wolfgang C Winkelmayer.;Christopher B Granger.; .
来源: Circulation. 2022年146卷23期1735-1745页
There are no randomized data evaluating the safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial fibrillation (AF).
277. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
作者: Hongyi Wu.;Lili Xu.;Xin Zhao.;Huanyi Zhang.;Kang Cheng.;Xiaoyan Wang.;Manhua Chen.;Guangping Li.;Jiangnan Huang.;Jun Lan.;Guanghe Wei.;Chi Zhang.;Yinman Wang.;Juying Qian.;Junbo Ge.; .
来源: Circulation. 2023年147卷3期212-222页
Dual antiplatelet therapy (DAPT) with aspirin as a background therapy has become the standard care after percutaneous coronary intervention. However, some adverse noncardiac effects limited the use of aspirin in clinical practice. Thus, evaluation of pharmacological alternatives to aspirin is attractive. Previous data indicated that indobufen could lessen the unwanted side effects of aspirin while retaining the antithrombotic efficacy, but its combination with a P2Y12 inhibitor still lacks randomized clinical trial evidence.
278. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
作者: Paul C Cremer.;Jeffrey B Geske.;Anjali Owens.;Wael A Jaber.;Serge C Harb.;Sara Saberi.;Andrew Wang.;Mark Sherrid.;Srihari S Naidu.;Hartzell Schaff.;Nicholas G Smedira.;Qiuqing Wang.;Kathy Wolski.;Kathy L Lampl.;Amy J Sehnert.;Steven E Nissen.;Milind Y Desai.
来源: Circ Cardiovasc Imaging. 2022年15卷12期e014986页
In the randomized phase 3 VALOR-HCM study (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) of patients with obstructive hypertrophic cardiomyopathy, mavacamten reduced the need for septal reduction therapy. Because mavacamten improves ventricular compliance, this sub-study examined the effects of treatment with this cardiac myosin inhibitor on diastolic function.
279. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
作者: Milind Y Desai.;Anjali Owens.;Jeffrey B Geske.;Kathy Wolski.;Sara Saberi.;Andrew Wang.;Mark Sherrid.;Paul C Cremer.;Srihari S Naidu.;Nicholas G Smedira.;Hartzell Schaff.;Ellen McErlean.;Christina Sewell.;Aarthi Balasubramanyam.;Kathy Lampl.;Amy J Sehnert.;Steven E Nissen.
来源: Circulation. 2023年147卷11期850-863页
Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) examined the effect of mavacamten on the need for SRT through week 32 in oHCM.
280. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
作者: Kim A Connelly.;C David Mazer.;Pankaj Puar.;Hwee Teoh.;Chao-Hung Wang.;Tamique Mason.;Farhad Akhavein.;Ching-Wen Chang.;Min-Hui Liu.;Ning-I Yang.;Wei-Siang Chen.;Yu-Hsiang Juan.;Erika Opingari.;Yaseen Salyani.;William Barbour.;Aryan Pasricha.;Shamon Ahmed.;Andrew Kosmopoulos.;Raj Verma.;Michael Moroney.;Ehab Bakbak.;Aishwarya Krishnaraj.;Deepak L Bhatt.;Javed Butler.;Mikhail N Kosiborod.;Carolyn S P Lam.;David A Hess.;Otavio Rizzi Coelho-Filho.;Myriam Lafreniere-Roula.;Kevin E Thorpe.;Adrian Quan.;Lawrence A Leiter.;Andrew T Yan.;Subodh Verma.
来源: Circulation. 2023年147卷4期284-295页
Sodium-glucose cotransporter 2 inhibitors have been demonstrated to promote reverse cardiac remodeling in people with diabetes or heart failure. Although it has been theorized that sodium-glucose cotransporter 2 inhibitors might afford similar benefits in people without diabetes or prevalent heart failure, this has not been evaluated. We sought to determine whether sodium-glucose cotransporter 2 inhibition with empagliflozin leads to a decrease in left ventricular (LV) mass in people without type 2 diabetes or significant heart failure.
|